Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry C Kitchener

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|July 12, 2016
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Lancet (London, England)|July 3, 2007
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialJorma Paavonen, David Jenkins, F Xavier Bosch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2020
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant TherapyAlicia León-Castillo, Stephanie M de Boer, Melanie E Powell, et al.
International Journal of Radiation Oncology, Biology, Physics|October 5, 2021
Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation TherapyBastiaan G Wortman, Cathalijne C B Post, Melanie E Powell, et al.
Clinical and Vaccine Immunology : CVI|February 6, 2015
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trialDan Apter, Cosette M Wheeler, Jorma Paavonen, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 29, 2019
The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndromeEmma J Crosbie, Neil A J Ryan, Mark J Arends, et al.
Obstetrical & Gynecological Survey|December 30, 2025
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 15, 2010
Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009Edward L Trimble, Michael J Birrer, William J Hoskins, et al.
The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|July 12, 2016
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Lancet (London, England)|July 3, 2007
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialJorma Paavonen, David Jenkins, F Xavier Bosch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2020
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant TherapyAlicia León-Castillo, Stephanie M de Boer, Melanie E Powell, et al.
International Journal of Radiation Oncology, Biology, Physics|October 5, 2021
Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation TherapyBastiaan G Wortman, Cathalijne C B Post, Melanie E Powell, et al.
Clinical and Vaccine Immunology : CVI|February 6, 2015
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trialDan Apter, Cosette M Wheeler, Jorma Paavonen, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 29, 2019
The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndromeEmma J Crosbie, Neil A J Ryan, Mark J Arends, et al.
Obstetrical & Gynecological Survey|December 30, 2025
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 15, 2010
Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009Edward L Trimble, Michael J Birrer, William J Hoskins, et al.
The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Pageof 9